MLN2201
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Species Reactivity
Human
IC50 & Target
Integrin β2
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
신청
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
N/A
-
Synonyms
YFC51.1; LDP-01
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Legos JJ, et al. Pharmacological interventions for stroke: failures and future. Expert Opin Investig Drugs. 2002 May;11(5):603-14. [Content Brief]
[2]. Legos JJ, et al. Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. Curr Opin Investig Drugs. 2003 Jul;4(7):847-58. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)